Dual vector technology enables Atsena to address diseases associated with mutations in large genes
Our dual vectors are constructed to deliver larger payloads for genetic mutations that are too large to treat with a single AAV vector.
Credit: MoA animation by Visual Science, 2022
Our dual vectors generate normal levels of expression in non-human primate retina
Atsena is leveraging a dual AAV vector approach in a preclinical program for MYO7A-associated Usher Syndrome (USH1B). Because the MYO7A cDNA is too long to fit in a single vector, it is split in half and each half is delivered via a separate AAV vector. Upon co-infection of cells with both vectors, the gene halves recombine to form full length MYO7A.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.